Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, over-turning a prior decision to reject NHS funding for the drug.
News
EU approval for AcelRx’ Dzuveo
AcelRx’ Dzuveo has won approval in the European Unionl for the management of acute moderate to severe pain in medically monitored settings.
Priority review for Genentech’s flu drug
The US Food and Drug Administration will undertake a priority review of Genentech’s experimental flu drug baloxavir marboxil in people aged 12 years and older.
Summit shares plummet on DMD drug failure
Shares in Oxford University spin out Summit Therapeutics have taken a nosedive after the firm’s flagship drug ezutromid failed to hit targets in a mid-stage trial in patients with Duchenne muscular dystrophy (DMD).
Puma shares jump as breast cancer drug approval seems likely
Shares in Puma Biotechnology shot up nearly 30 percent on news that the firm’s breast cancer drug is now likely to get a green light from European regulators.
Pfizer names winners of Healthcare Hub Challenge
Medopad, Perfect Ward and Inhealthcare have been named as this year’s winners of Pfizer’s Healthcare Hub: London challenge.
AbbVie, Calico extend age-related diseases collaboration
AbbVie and Calico have expanded their agreement to develop treatments for age-related diseases for a further three years.
AZ/MSD pursue wider indication for Lynparza on trial success
AstraZeneca and MSD have unveiled trial results showing that Lynparza significantly extended the time patients with ovarian cancer lived without their disease worsening in the first-line maintenance setting, which could significantly expand the drug’s reach.
NHS has lost more than 6,000 beds in four years, says BMA
The NHS has lost more than 6,000 beds across the country over the last four years, according to new figures published by the British Medical Association (BMA).
UK Space Agency links with NHS England to find health innovations
The UK Space Agency will stream up to £4 million into find hi-tech solutions to major health and care challenges facing the NHS in its 70th anniversary year, under a joint initiative with NHS England.
Pierre Fabre, Array showcase potential of triple therapy for CRC
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
NICE, Greater Manchester extend health partnership
A collaboration between Greater Manchester and the National Institute for Health and Care Excellence (NICE) that seeks to improve the health of the local population has been expanded for a further three years.
FDA approves GW’s cannabinoid drug Epidiolex
GW Pharmaceuticals’ Epidiolex has become the first cannabinoid prescription medicine to be approved in the US, winning clearance to treat two rare forms of epilepsy.
PharmaTimes Media teams up with leading bowel cancer charity
PharmaTimes Media has announced an important new partnership with Bowel Cancer UK and Beating Bowel Cancer ahead of its 2018 Communications Team of the Year competition.
Novo’s Ozempic beats Lilly’s Trulicity on weight loss
Novo Nordisk has announced new data showing that its once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist Ozempic provided greater weight reductions than Eli Lilly’s rival drug Trulicity in adults with type II diabetes.
